Agomab Doses First Patient in Ontunisertib Crohn’s Disease Phase 2b Trial: A Pivotal Step
Ontunisertib Crohn’s disease Phase 2b trial opens: first patient dosed in NOV-ERA, about 320 adults. The drug is unapproved and efficacy is unproven.
Agomab Doses First Patient in Ontunisertib Crohn’s Disease Phase 2b Trial: A Pivotal Step
Ontunisertib Crohn’s disease Phase 2b trial opens: first patient dosed in NOV-ERA, about 320 adults. The drug is unapproved and efficacy is unproven.
Abram Scientific DARPA Contract: Bold Win for Rapid Portable Blood-Coagulation Testing
Abram Scientific DARPA contract of up to $8.3M backs CoagCare, a portable clotting test. It is not FDA-cleared; speed claims are the company’s.
Google Flo Health Partnership: Powerful Step Linking Cycle Tracking and Wearable Data
Google Flo Health partnership links cycle tracking with wearable data from early 2027. The investment amount is undisclosed and the features are wellness tools.
IceCure ProSense Breast Cancer Cryoablation: Promising 12-Month Data Reported at EUSOBI 2026
IceCure ProSense breast cancer cryoablation: the company reports 97.5% 12-month response in 40 patients. Study design and safety data were not disclosed.
Vantis Vascular Wins CrossFAST 6F FDA Clearance: Powerful New Option for Complex PCI
CrossFAST 6F FDA clearance adds a larger-lumen microcatheter for complex PCI. It is a new configuration; no outcome data were reported.
Oorja Bio Begins ORJ-001 Pulmonary Fibrosis Trial: A Critical Test for a New Approach
ORJ-001 pulmonary fibrosis trial begins: Oorja Bio screens its first patient in Phase 2. The drug is experimental and no efficacy results exist yet.
Soufflé Therapeutics $135 Million Funding: Powerful Boost for RNA Drugs
Soufflé Therapeutics $135 million funding backs RNA drugs for FSHD and heart failure. The treatments are experimental; no new human data were reported.
FDA Backs Proposed Stem Cell Trial for Treatment-Resistant Crohn’s Disease
StemSmart Crohn’s disease clinical trial gets positive FDA pre-IND feedback on 6 of 7 questions; a viral safety issue remains. Not a marketing approval.
Lasix ONYU Home Study: 18 of 21 Heart Failure Patients Avoided Admission
Early data say 18 of 21 heart failure patients were treated at home with Lasix ONYU. What hospital leaders can and cannot conclude from a single-arm study.
